Literature DB >> 28394367

Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.

A Liou1, J T Wahlstrom2, C C Dvorak2, B N Horn2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28394367     DOI： 10.1038/bmt.2017.45

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  F Dazzi; R M Szydlo; N C Cross; C Craddock; J Kaeda; E Kanfer; K Cwynarski; E Olavarria; A Yong; J F Apperley; J M Goldman
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.

Authors:  Eva Rettinger; Andre M Willasch; Hermann Kreyenberg; Arndt Borkhardt; Wolfgang Holter; Bernhard Kremens; Brigitte Strahm; Wilhelm Woessmann; Christine Mauz-Koerholz; Bernd Gruhn; Stefan Burdach; Michael H Albert; Paul-Gerhardt Schlegel; Thomas Klingebiel; Peter Bader
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

3.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.

Authors:  Michael A Pulsipher; Chris Carlson; Bryan Langholz; Donna A Wall; Kirk R Schultz; Nancy Bunin; Ilan Kirsch; Julie M Gastier-Foster; Michael Borowitz; Cindy Desmarais; David Williamson; Michael Kalos; Stephan A Grupp
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

Review 4.  Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.

Authors:  Leo Luznik; Ephraim J Fuchs
Journal:  Cancer Control       Date:  2002 Mar-Apr       Impact factor: 3.302

5.  Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.

Authors:  B Horn; S Soni; S Khan; A Petrovic; N Breslin; M Cowan; G Pelle-Day; E Cooperstein; L-A Baxter-Lowe
Journal:  Bone Marrow Transplant       Date:  2008-10-27       Impact factor: 5.483

6.  Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.

Authors:  Biljana Horn; Aleksandra Petrovic; Justin Wahlstrom; Christopher C Dvorak; Denice Kong; Jimmy Hwang; Jueleah Expose-Spencer; Michael Gates; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-31       Impact factor: 5.742

7.  Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?

Authors:  Peter Bader; Hermann Kreyenberg; Walter Hoelle; Gregor Dueckers; Rupert Handgretinger; Peter Lang; Bernhard Kremens; Dagmar Dilloo; Karl-Walter Sykora; Martin Schrappe; Charlotte Niemeyer; Arend Von Stackelberg; Bernd Gruhn; Günter Henze; Johann Greil; Dietrich Niethammer; Klaus Dietz; James F Beck; Thomas Klingebiel
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

8.  Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Chen-Hua Yan; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Yan-Rong Liu; Huan Chen; Wei Han; Yu Wang; Ya-Zhen Qin; Xiao-Jun Huang
Journal:  Blood       Date:  2012-02-14       Impact factor: 22.113

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.

Authors:  P Rujkijyanont; C Morris; G Kang; K Gan; C Hartford; B Triplett; M Dallas; A Srinivasan; D Shook; A Pillai; C-H Pui; W Leung
Journal:  Blood Cancer J       Date:  2013-08-30       Impact factor: 11.037
  10 in total
  2 in total

Review 1.  A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.

Authors:  Amanda G Blouin; Fei Ye; Jenifer Williams; Medhat Askar
Journal:  Hum Immunol       Date:  2021-08-14       Impact factor: 2.211

2.  Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.

Authors:  Gabriela Llaurador; Eileen Nicoletti; Susan E Prockop; Susan Hsu; Kirsten Fuller; Audrey Mauguen; Richard J O'Reilly; Jaap J Boelens; Farid Boulad
Journal:  Transplant Cell Ther       Date:  2021-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.